| Titre : | Repurposing chlorpromazine to treat COVID-19: the reCoVery study (2020) |
| Auteurs : | PLAZE M ; ATTALI D ; PETIT AC ; BLATZER M ; SIMON LORIERE E ; VINCKIER F ; CACHAI A ; CHRETIEN F ; GAILLARD RAPHAËL |
| Type de document : | Article |
| Dans : | ENCEPHALE (3 vol 48, 2020) |
| Article en page(s) : | 169-172 |
| Descripteurs |
[SANTEPSY] COMORBIDITE [SANTEPSY] CORONAVIRUS [SANTEPSY] ESSAI CLINIQUE [SANTEPSY] PANDEMIE [SANTEPSY] PATHOLOGIE PSYCHIATRIQUE |
| Mots-clés libres: | CHLORPROMAZINE |
| Résumé : | The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity [Extrait du résumé] |
| En ligne : | https://www.em-premium.com/article/1372496 |
Bibliothèque Médicale et Professionnelle
Bibliothèque Médicale & Professionnelle
Accueil
Sélection de la langue
Se connecter
Adresse
Bibliothèque Médicale et Professionnelle04 74 52 28 07
contact
